Cookson B D
Laboratory of Hospital Infection, PHLS Central Public Health Laboratory, London, UK.
J Antimicrob Chemother. 1998 Jan;41(1):11-8. doi: 10.1093/jac/41.1.11.
Mupirocin was introduced into clinical practice in the UK in 1985, and has proved to be an extremely effective treatment of skin infections and one of the most successful topical antibiotics for the clearance of nasal Staphylococcus aureus isolates including those resistant to methicillin. It is currently registered for use in more than 90 countries worldwide. Unfortunately resistance was described shortly after its initial use. Many of the issues regarding its use are reviewed here, together with the mechanisms, genetics, surveillance and epidemiology of resistance, particularly in staphylococci. The various factors that increase resistance and how they might be controlled are also discussed.
莫匹罗星于1985年在英国投入临床使用，已被证明是治疗皮肤感染的极为有效的药物，也是清除鼻腔金黄色葡萄球菌分离株（包括耐甲氧西林菌株）最成功的外用抗生素之一。目前它在全球90多个国家注册使用。不幸的是，在其首次使用后不久就出现了耐药性。本文综述了许多与莫匹罗星使用相关的问题，以及耐药性的机制、遗传学、监测和流行病学，特别是葡萄球菌中的耐药情况。还讨论了增加耐药性的各种因素以及如何控制这些因素。
